Characteristics of Epstein-Barr virus activation of human B lymphocytes

Epstein-Barr virus (EBV) will infect at least every third cell if exposed in vitro to an extensively purified B cell population from human peripheral blood. About 10% of such infected cells will be driven into immunoglobulin synthesis and secretion, as judged by the indirect protein A plaque assay. The appearance of EB nuclear antigen, de novo DNA synthesis, and immunoglobulin secretion are linked phenomena accompanying infection as judged by viral dilution experiments, which yield kinetics of a one-hit order. Induction of immunoglobulin secretion in B cells by EBV requires de novo synthesis of DNA, and consequently, nontransforming EBV (P3HR1) will not induce immunoglobulin secretion and will also specifically block such induction from subsequently added EBV. The termination of immunoglobulin induction by EBV in short-term cultures appears to be T cell dependent.

[1]  A G Bird,et al.  A New Approach to the Study of Human B Lymphocyte Function Using an Indirect Plaque Assay and a Direct B Cell Activator , 1979, Immunological reviews.

[2]  M. Konn,et al.  Immunofluorescence and Herpes-Type Virus Particles in the P3HR-1 Burkitt Lymphoma Cell Line , 1967, Journal of virology.

[3]  G. Klein,et al.  Cellular localization of an Epstein‐Barr virus (EBV)‐associated complement‐fixing antigen in producer and non‐producer lymphoblastoid cell lines , 1973, International journal of cancer.

[4]  U. Andersson,et al.  Cellular mechanisms of restricted immunoglobulin formation in the human neonate , 1980, European journal of immunology.

[5]  G. Klein,et al.  The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV , 1971, International journal of cancer.

[6]  I. Ernberg,et al.  Epstein-Barr virus (EBV) receptors, complement receptors, and EBV infectibility of different lymphocyte fractions of human peripheral blood. I. Complement receptor distribution and complement binding by separated lymphocyte subpopulations. , 1978, Cellular immunology.

[7]  V. Diehl,et al.  Demonstration of a Herpes Group Virus in Cultures of Peripheral Leukocytes from Patients with Infectious Mononucleosis , 1968, Journal of virology.

[8]  D. Thorley-Lawson.  The suppression of Epstein-Barr virus infection in vitro occurs after infection but before transformation of the cell. , 1980, Journal of immunology.

[9]  H. Fudenberg,et al.  Polyclonal activation of human peripheral blood B lymphocytes by formaldehyde-fixed Salmonella paratyphi B. I. Immunoglobulin production without DNA synthesis , 1981, The Journal of experimental medicine.

[10]  M. Epstein,et al.  Various forms of Epstein-Barr virus infection in man: established facts and a general concept. , 1973, Lancet.

[11]  M. Epstein,et al.  Comparative studies on adult donor lymphocytes infected by EB virus in vivo or in vitro: Origin of transformed cells arising in co‐cultures with foetal lymphocytes , 1977, International journal of cancer.

[12]  S. Britton,et al.  A Live Human B‐Cell Activator Operating in Isolation of Other Cellular Influences , 1979, Scandinavian journal of immunology.

[13]  J. Niederman,et al.  Mitotic EBNA-positive lymphocytes in peripheral blood during infectious mononucleosis , 1980, Nature.

[14]  J. Schröder,et al.  Activation to IgG secretion by lipopolysaccharide requires several proliferation cycles. , 1979, Journal of immunology.

[15]  A. Bøyum,et al.  Isolation of mononuclear cells and granulocytes from human blood. , 1968 .